In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
UC San Diego School of Medicine researchers identified chemical compounds that prevent stress-induced clumping of TDP-43 protein in ALS motor neurons grown in the lab — a starting point for new ALS therapeutics.
UC San Diego Health is among 31 health facilities selected from across the state to participate in the California Bridge Program, an accelerated, 18-month training program for health care providers to enhance access to around-the-clock treatment for patients with opioid use disorder.
Researchers at University of California San Diego School of Medicine will expand a statewide program to prevent driving under the influence of alcohol, cannabis and prescription drugs.
New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.
Netherton syndrome is exacerbated by the presence of Staphylococcus aureus and Staphylococcus epidermidis living on human skin report University of California San Diego School of Medicine researchers.
A novel research study by UC San Diego researchers will determine whether testing stored blood drops, recorded at birth, for 1,000 different molecules and chemicals can help predict autism risk years before symptoms would likely appear.
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
Health Media Contacts
Find the best contact for health-related media inquiries.
